MyomP1 peptide
MyomP1 peptide is a functionalized modification group targeting apolipoprotein E (ApoE). MyomP1 peptide restricts the adsorption of ApoE on lipid nanoparticles, reduces ApoE-mediated hepatic uptake, and confers liver detargeting. MyomP1 peptide attenuates innate immune activation by reducing the expression of inflammatory markers and decreasing macrophage recruitment at the injection site. MyomP1 peptide is useful for research on rare muscle diseases.
For research use only. We do not sell to patients.
- Formula: C85H155N33O17
- Molecular Weight:1911.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
apoE |
In Vitro
MyomP1 peptide-functionalized pDNA-LNP (pDNA-MyomP1-LNP) treatment of C2C12 mouse myoblasts and myotubes at a dose of 1 μg/1.2×106 cells for 24 h significantly enhances luciferase transduction efficiency, but reduces myoblast viability by 18%[1].
MyomP1 peptide-functionalized mRNA-LNP (mRNA-MyomP1-LNP) treats C2C12 mouse myoblasts and myotubes at a dose of 1 μg/1.2×106 cells for 24 h, producing up to 14-fold RLU/μg protein in myoblasts and 22-fold in myotubes, with protein expression increased 9-fold and 75-fold, respectively, myoblast viability reduced by 30%, and no significant toxicity in myotubes[1].
MyomP1 peptide-functionalized mRNA-LNPs transduce human C25 myoblasts, resulting in a 3.6-fold increase in luciferase activity and a 7-fold increase in protein expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MyomP1 peptide-functionalized mRNA-LNPs (1 μg; i.m.; single injection) confer liver de-targeting after intramuscular injection and reduce innate immune activation[1].
MyomP1 peptide-functionalized mRNA-LNPs (3 μg; i.v.; single injection) reduce liver expression after systemic injection and are associated with mild modulation of acquired immune cell populations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N mice (8 weeks old)[1]
-
Dosage:1 μg
-
Administration:i.m.; single injection
-
Result:Increased luminescence signal by 10-fold in the TA muscle compared to pDNA-LNPs.
Achieved an overall luminescence of approximately 2.5E+4 p/s/cm2/sr.
Produced a 27.7-fold lower signal in the TA muscle compared with mRNA-MyomP1-LNPs.\nDecreased liver signal by 51-fold at 6 h and 7-fold at 24 h compared with LNPs.
Showed lower liver transduction than Scr-MyomP1-LNP at both 6 h and 24 h post-injection.
Led to a significant decrease in the expression of IRF7, CCL2, and CXCL10 in lymph nodes at 6 h post-injection.
Reduced macrophage infiltration in TA muscles.
-
Animal Model:C57BL/6N mice (8 weeks old)[1]
-
Dosage:3 μg
-
Administration:i.v. (retro-orbital); single injection
-
Result:Showed 8.7-fold lower liver transduction compared to mRNA-LNP.
Showed 5.5-fold lower liver transduction compared to mRNA-LNP-DBCO.
Significantly higher gastrocnemius-to-liver luciferase activity ratio compared to control formulations.
Increased proportion of CD4+ T cells and a reduced proportion of B cells compared to mRNA-LNP.
Chemical Information
-
Molecular Weight 1911.35
-
Formula C85H155N33O17
-
Sequence
Arg-Gln-His-Leu-Leu-Pro-Leu-Leu-Arg-Arg-Leu-Ala-Arg-Arg-Leu
-
Sequence Shortening
RQHLLPLLRRLARRL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MyomP1 peptide Related Classifications
HY-P12363 Related Classifications
Powered by Bioz